Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.

V Meininger1, B Asselain, P Guillet

  • 1Fédération des Maladies du Système Nerveux, Pavillon Paul Castaigne, AP-HP, Hôpital de la Salpétrière, Paris, France. vincent.meininger@psl.aphp.fr

Neurology
|January 13, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018).

ESMO real world data and digital oncology·2026
Same author

Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).

ESMO open·2025
Same author

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Real-world first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer: the CAPSTAN CRC study.

ESMO open·2022
Same author

Lazy Sundays: role of day of the week and reactivity on objectively measured physical activity in older people.

European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity·2019
Same author

Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival.

Respiratory medicine and research·2019

Pentoxifylline did not improve survival in patients with amyotrophic lateral sclerosis (ALS) treated with riluzole. This drug should be avoided in ALS patients due to lack of benefit and potential harm.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
  • Riluzole is a standard treatment for ALS.
  • Pentoxifylline is a US Food and Drug Administration-approved drug with potential therapeutic properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of pentoxifylline in ALS patients already receiving riluzole.
  • To determine if pentoxifylline impacts survival or functional decline in ALS.

Main Methods:

  • A double-blind, randomized, placebo-controlled, multicenter trial involving 400 ALS patients.
  • Patients received either placebo or 1.2 g of pentoxifylline daily.
  • Primary outcome was all-cause mortality; secondary outcomes included functional and muscle strength deterioration.

Related Experiment Videos

Main Results:

  • Pentoxifylline did not significantly improve survival; adjusted risk of death was higher in the pentoxifylline group (adjusted risk 1.43, p = 0.02).
  • Secondary outcome analyses did not reveal a similar negative effect on functional measures.
  • Adverse events like nausea and dysphagia were reported but were reversible.

Conclusions:

  • Pentoxifylline offers no benefit for ALS patients treated with riluzole and should be avoided.
  • Discrepancies between survival and functional outcomes highlight the need for careful endpoint selection in ALS clinical trials.